Hospital Budget Impact Research Articles

EE538 Hospital Budget Impact of a Lung Suite Navigation Platform to Diagnose and Treat Lung Cancer Patients

EE538 Hospital Budget Impact of a Lung Suite Navigation Platform to Diagnose and Treat Lung Cancer Patients

Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis

Background: Targeted therapy for cancer is becoming more frequent as the understanding of the molecular pathogenesis increases. Molecular testing must be done to use targeted therapy. Unfortunately, the testing turnaround time can delay the initiation of targeted therapy. Objective: To investigate the impact of a next-generation sequencing (NGS) machine in the hospital that would allow for in-house NGS testing of metastatic non-small cell lung cancer (mNSCLC) in a US setting. Methods: The differences between 2 hospital pathways were established with a cohort-level decision tree that feeds into a Markov model. A pathway that used in-house NGS (75%) and the use of external laboratories (so-called send-out NGS) (25%), was compared with the standard of exclusively send-out NGS. The model was from the perspective of a US hospital over a 5-year time horizon. All cost input data were in or inflated to 2021 USD. Scenario analysis was done on key variables. Results: In a hospital with 500 mNSCLC patients, the implementation of in-house NGS was estimated to increase the testing costs and the revenue of the hospital. The model predicted a $710 060 increase in testing costs, a $1 732 506 increase in revenue, and a $1 022 446 return on investment over 5 years. The payback period was 15 months with in-house NGS. The number of patients on targeted therapy increased by 3.38%, and the average turnaround time decreased by 10 days when in-house NGS was used. Discussion: Reducing testing turnaround time is a benefit of in-house NGS. It could contribute to fewer mNSCLC patients lost to second opinion and an increased number of patients on targeted therapy. The model outcomes predicted that, over a 5-year period, there would be a positive return on investment for a US hospital. The model reflects a proposed scenario. The heterogeneity of hospital inputs and the cost of send-out NGS means context-specific inputs are needed. Conclusion: Using in-house NGS testing could reduce the testing turnaround time and increase the number of patients on targeted therapy. Additional benefits for the hospital are that fewer patients will be lost to second opinion and that in-house NGS could generate additional revenue.

Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis.

Background: Targeted therapy for cancer is becoming more frequent as the understanding of the molecular pathogenesis increases. Molecular testing must be done to use targeted therapy. Unfortunately, the testing turnaround time can delay the initiation of targeted therapy. Objective: To investigate the impact of a next-generation sequencing (NGS) machine in the hospital that would allow for in-house NGS testing of metastatic non-small cell lung cancer (mNSCLC) in a US setting. Methods: The differences between 2 hospital pathways were established with a cohort-level decision tree that feeds into a Markov model. A pathway that used in-house NGS (75%) and the use of external laboratories (so-called send-out NGS) (25%), was compared with the standard of exclusively send-out NGS. The model was from the perspective of a US hospital over a 5-year time horizon. All cost input data were in or inflated to 2021 USD. Scenario analysis was done on key variables. Results: In a hospital with 500 mNSCLC patients, the implementation of in-house NGS was estimated to increase the testing costs and the revenue of the hospital. The model predicted a $710 060 increase in testing costs, a $1 732 506 increase in revenue, and a $1 022 446 return on investment over 5 years. The payback period was 15 months with in-house NGS. The number of patients on targeted therapy increased by 3.38%, and the average turnaround time decreased by 10 days when in-house NGS was used. Discussion: Reducing testing turnaround time is a benefit of in-house NGS. It could contribute to fewer mNSCLC patients lost to second opinion and an increased number of patients on targeted therapy. The model outcomes predicted that, over a 5-year period, there would be a positive return on investment for a US hospital. The model reflects a proposed scenario. The heterogeneity of hospital inputs and the cost of send-out NGS means context-specific inputs are needed. Conclusion: Using in-house NGS testing could reduce the testing turnaround time and increase the number of patients on targeted therapy. Additional benefits for the hospital are that fewer patients will be lost to second opinion and that in-house NGS could generate additional revenue.

EE345 Strengths and Limitations of Different Costing Approaches Used for Hospital Budget Impact Models: Application to Imaging Guidance in Left Atrial Appendage Occlusion Procedures

Hospital budget impact models can be simpler to build than cost-effectiveness models; however, they can be more complicated to inform given challenges with data availability, various decision-maker perspectives, and complexities around interpretation of costs, charges, and reimbursement. This study evaluates the strengths and weaknesses of two costing approaches used for economic evaluation related to image guidance in left atrial appendage occlusion (LAAO) procedures.

Economic impact of a rapid, on‐demand ADAMTS‐13 activity assay for the diagnosis of thrombotic thrombocytopenic purpura

BackgroundThrombotic thrombocytopenic purpura (TTP) is a rare, life‐threatening thrombotic microangiopathy (TMA), characterized by ADAMTS‐13 activity <10%. ADAMTS‐13 activity assays are typically performed in reference laboratories with a turnaround time of several days. First‐line treatment for TTP, therapeutic plasma exchange (TPE), typically starts while results are pending. The automated, on‐demand HemosIL AcuStar ADAMTS‐13 Activity assay provides results in under an hour, which could reduce unnecessary TPE use and associated costs. ObjectivesTo estimate the hospital budget impact in the United States, United Kingdom, and France of using a rapid ADAMTS‐13 activity assay. MethodsWe compared routine use of a rapid assay in adults with TMA with a scenario in which results take 3 days. Model structure and variables were based on published literature, plus survey and interviews of five clinicians from the three countries. Costs for the ADAMTS‐13 activity assays and TPE were included. ResultsModel results suggest that if an on‐demand, rapid ADAMTS‐13 activity assay is used, US, UK, and French hospitals could save $18 million, £1.2 million, and €1.6 million annually, respectively. This equates to $10 788, £3497, and €4700 saved per patient with TMA in the United States, United Kingdom, and France. The model is most sensitive to the exact split of diagnoses of TMA cases, as savings accrue from non‐TTP diagnoses. ConclusionsIn patients with TMA, use of a rapid, on‐demand ADAMTS‐13 activity assay such as the HemosIL AcuStar ADAMTS‐13 Activity assay has the potential to be cost saving for hospitals.

POSA289 Hospital Budget Impact Analysis on the Use of EEG ESI for Complex, Non-Lesional Epilepsy Surgery Evaluation

Approximately 30-40%1 of epilepsy patients are refractory to available medications, and may be candidates for resective surgery, which can be an effective treatment option. As a result, there is an increasing number of epilepsy surgery evaluations. However, the success of such surgery is heavily dependent on identifying the area of seizure origin (foci). In particular, complex, non-lesional epilepsy foci are often the most difficult to locate and thus, have the lowest seizure freedom rate of 27-35%2,3.

Budget Impact of Restrictive Strategy Versus Usual Care for Cholecystectomy (SECURE-Trial)

ObjectivesA cost-effectiveness analysis of a multicenter randomized-controlled trial comparing restrictive strategy versus usual care in patients with gallstones showed that savings by restrictive strategy could not compensate for the lower proportion of pain-free patients. However, four subgroups based on combined stratification factors resulted in less cholecystectomies and more pain-free patients in restrictive strategy (female-low volume-BMI > 30, female-low volume-BMI25-30, female-high volume-BMI25-30, and male-low volume-BMI < 25). The aim of this study was to explore the budget impact from a hospital healthcare perspective of implementation of restrictive strategy in these subgroups. MethodsData of the SECURE-trial were used to calculate the hospital budget impact with a time horizon of four years. Based on a study into practice variation, about 19% of hospitals treat patients according restrictive strategy. This represents the proportion of patients treated according restrictive strategy at the start of budget period. Three subanalyses were performed: a scenario analysis in which 30% of patients fall under a restrictive strategy in clinical practice, a sensitivity analysis in which we calculated the budget impact with the low and high 95% confidence limits of the expected future number of patients, a subgroup analysis in which restrictive strategy was also implemented in two additional subgroups (male-high volume-BMI < 25 and female-high volume-BMI >30). ResultsBudget impact analysis showed savings of €6.7-€15.6 million (2.2%-5.6%) for the period 2021-2024/2025 by implementing the restrictive strategy in the four subgroups and provision of usual care in other patients. Sensitivity analysis with 30% of patients already in the restrictive strategy at the start of the budget period, resulted in savings between €5.4 million and €14.0 million (1.7%-5.0%). ConclusionPerforming a restrictive strategy for selection of cholecystectomy in subgroups of patients and provision of usual care in other patients will result in a lower overall hospital budget needed to treat patients with abdominal pain and gallstones. Trial registrationThe Netherlands National Trial Register NTR4022. Registered on June 5, 2013.

PDG6 Budget Impact Analysis for Oliceridine in the Management of Moderate to Severe Acute Postoperative Pain

Use of conventional opioids for postoperative pain are associated with adverse events (ORAEs) that can affect health outcomes, compromising analgesia. Oliceridine, a new class of μ-opioid receptor IV agonist , is selective for G-protein signaling (achieving analgesia) with limited recruitment of β-arrestin (associated with ORAEs). Here we estimate the budget impact of oliceridine vs morphine for postoperative pain. We compared costs & outcomes of patients managed with demand dosing (DD) of oliceridine (0.35mg and 0.5mg) to those with morphine (1mg), using a decision tree with a 24-hour time horizon and sample population of 1,000 surgeries for each arm. Three common and costly ORAEs; respiratory depression (SpO2<90%, RD), vomiting, and somnolence were utilized. Costs were enumerated as differences in cost of analgesics and resources utilized to manage the 3 ORAEs within 24 hours post-surgery. Risk ratios (RR) were based on AE rates observed in two controlled Phase-3 studies. RRs were then applied to AE rates observed in an open-label Phase-3 study of oliceridine to estimate AE incidence in real-world sample. Costs of all analgesics and antiemetics were tabulated based on rates observed in Phase-3 studies. Standard cost weights from national discharge data and literature-sources were used to estimate hospital budget impact & costs for each AE. Average price was set to $100/day for oliceridine and $15/day for morphine. Incremental cost of RD, vomiting and somnolence was estimated at $3,975, $1,035 and $991, respectively. Use of oliceridine resulted in greater medication expenditures vs. morphine ($127,181 vs $30,558). However, overall hospital costs resulting from resources for managing AEs were lower for oliceridine vs morphine ($528,424 vs $852, 429), with net savings of $324,005 for each 1,000 treated patients. Use of oliceridine vs morphine for postoperative pain is expected to increase pharmacy costs but have a favorable overall budget impact.

A device category economic model of electrosurgery technologies across procedure types: a U.S. hospital budget impact analysis

Aims The electrosurgical technology category is used widely, with a diverse spectrum of devices designed for different surgical needs. Historically, hospitals are supplied with electrosurgical devices from several manufacturers, and those devices are often evaluated separately; it may be more efficient to evaluate the category holistically. This study assessed the health economic impact of adopting an electrosurgical device-category from a single manufacturer. Methods A budget impact model was developed from a U.S. hospital perspective. The uptake of electrosurgical devices from EES (Ethicon Electrosurgery), including ultrasonic, advanced bipolar, smoke evacuators, and reusable dispersive electrodes were compared with similar MED (Medical Energy Devices) from multiple manufacturers. It was assumed that an average hospital performed 10,000 annual procedures 80% of which involved electrosurgery. Current utilization assumed 100% MED use, including advanced energy, conventional smoke mitigation options (e.g. ventilation, masks), and single-use disposable dispersive electrode devices. Future utilization assumed 100% EES use, including advanced energy devices, smoke evacuators (i.e. 80% uptake), and reusable dispersive electrodes. Surgical specialties included colorectal, bariatric, gynecology, thoracic and general surgery. Systematic reviews, network meta-analyses, and meta-regressions informed operating room (OR) time, hospital stay, and transfusion model inputs. Costs were assigned to model parameters, and price parity was assumed for advanced energy devices. The costs of disposables for dispersive electrodes and smoke-evacuators were included. Results The base-case analysis, which assessed the adoption of EES instead of MED for an average U.S. hospital predicted an annual savings of $824,760 ($101 per procedure). Savings were attributable to associated reductions with EES in OR time, days of hospital stay, and volume of disposable electrodes. Sensitivity analyses were consistent with these base-case findings. Conclusions Category-wide adoption of electrosurgical devices from a single manufacturer demonstrated economic advantages compared with disaggregated product uptake. Future research should focus on informing comparisons of innovative electrosurgical devices.

PMD10 A BUDGET IMPACT AND RETURN ON INVESTMENT ANALYSIS OF INCORPORATING DRUG – ELUTING STENTS INTO A CHINESE HOSPITAL MEDICAL DEVICE FORMULARY — A HOSPITAL PERSPECTIVE

Recent studies have demonstrated that Resolute Integrity drug-eluting stent (RI-DES) was found to be non-inferior to Xience Xpedition drug-eluting stent (XX-DES) & Synergy drug-eluting stent (Synergy-DES). Given that the PCI cost can be impacted by choice of DES, this study is to evaluate the China hospital budget impact of using different DES combinations in hospitals. A budget impact model was developed to compare two scenarios: the implantation of RI-DES and XX-DES or RI-DES and Synergy-DES. The average PCI procedure volume was assumed as 1,500 per year. The baseline market share and the subsequent annual growth rate of DES were estimated based on the IQVIA data. PCI cost parameters were collected from electronic medical records and bills of 303 patients. The unit price of DES was taken from tender price. The budget difference between subsequent year and base year in two scenarios was calculated respectively. RI-DES has higher average unit price, but lower average unit number used per PCI compared with XX-DES, which lowers total PCI cost. Under DRG payments, the use of RI-DES at 10% annual growth rate will generate ¥19,791 in 2020 and ¥39,582 in 2021 in hospital savings. RI-DES has same average unit number used per PCI, but lower average unit price compared to Synergy-DES, which reduces total PCI cost. Compared to Synergy-DES, hospitals increase the use of RI- DES at 10% annually, which will achieve savings ¥77,583 in 2020 and ¥155,166 in 2021. One-way sensitivity analysis indicated that the model is robust. With no clinical efficacy difference demonstrated among RI-DES, XX-DES and Synergy-DES, under DRG systems, the increased use of RI-DES realizes considerable cost savings and create positive returns from the hospital perspective.

A US hospital budget impact analysis of a skin closure system compared with standard of care in hip and knee arthroplasty.

BackgroundMedicare’s mandatory bundle for hip and knee arthroplasty necessitates provider accountability for quality and cost of care to 90 days, and wound closure may be a key area of consideration. The DERMABOND® PRINEO® Skin Closure System (22 cm) combines a topical skin adhesive with a self-adhering mesh without the need for dressing changes or suture or staple removal. This study estimated the budget impact of the Skin Closure System compared to other wound closure methods for hip and knee arthroplasty.MethodsA 90-day economic model was developed assuming 500 annual hip/knee arthroplasties for a typical US hospital setting. In current practice, wound closure methods for the final skin layer were set to 50% sutures and 50% staples. In future practice, this distribution shifted to 20% sutures, 20% staples, and 60% Skin Closure System. Health care resources included materials (eg, staplers, steri-strips, and traditional/barbed sutures), standard or premium dressings, outpatient visits, and home care visits. An Expert Panel, comprised of three orthopedic physician assistants, two orthopedic surgeons, and a home health representative, was used to inform several model parameters. Other inputs were informed by national data or literature. Unit costs were based on list prices in 2016 US dollars. Uncertainty in the model was explored through one-way sensitivity and alternative scenario analyses.ResultsThe analysis predicted that use of Skin Closure System in the future practice could achieve cost savings of $56.70 to $79.62 per patient, when standard or premium wound dressings are used, respectively. This translated to an annual hospital budgetary savings ranging from $28,349 to $39,809 when assuming 500 arthroplasties. Dressing materials and postoperative health care visits were key model drivers.ConclusionsUse of the Skin Closure System may provide cost savings within hip and knee arthroplasties due to decreases in resource utilization in the postacute care setting.

Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model.

BackgroundUS FDA draft guidance includes pathogen reduction (PR) or secondary rapid bacterial testing (RT) in its recommendations for mitigating risk of platelet component (PC) bacterial contamination. An interactive budget impact model was created for hospitals to use when considering these technologies.MethodsA Microsoft Excel model was built and populated with base-case costs and probabilities identified through literature search and a survey of US hospital transfusion service directors. Annual costs of PC acquisition, testing, wastage, dispensing/transfusion, sepsis, shelf life, and reimbursement for a mid-sized hospital that purchases all of its PCs were compared for four scenarios: 100% conventional PCs (C-PC), 100% RT-PC, 100% PR-PC, and 50% RT-PC/50% PR-PC.ResultsAnnual total costs were US$3.64, US$3.67, and US$3.96 million when all platelets were C-PC, RT-PC, or PR-PC, respectively, or US$3.81 million in the 50% RT-PC/50% PR-PC scenario. The annual net cost of PR-PC, obtained by subtracting annual reimbursements from annual total costs, is 6.18% above that of RT-PC. Maximum usable shelf lives for C-PC, RT-PC, and PR-PC are 3.0, 5.0, and 3.6 days, respectively; hospitals obtain PR-PC components earliest at 1.37 days.ConclusionThe model predicts minimal cost increase for PR-PC versus RT-PC, including cost offsets such as elimination of bacterial detection and irradiation, and reimbursement. Additional safety provided by PR, including risk mitigation of transfusion-transmission of a broad spectrum of viruses, parasites, and emerging pathogens, may justify this increase. Effective PC shelf life may increase with RT, but platelets can be available sooner with PR due to elimination of bacterial detection, depending on blood center logistics.

PMD102 - Cost and Shelf-Life Implications of Pathogen-Reduced Platelets: A Hospital Budget Impact Model

PMD102 - Cost and Shelf-Life Implications of Pathogen-Reduced Platelets: A Hospital Budget Impact Model

PMD109 - A Hospital Budget Impact Model to Estimate the Impact Associated with Phasix™ and Phasix™ St Mesh Versus Stratticetm Matrix in Complex Ventral Hernia Repair Procedures

PMD109 - A Hospital Budget Impact Model to Estimate the Impact Associated with Phasix™ and Phasix™ St Mesh Versus Stratticetm Matrix in Complex Ventral Hernia Repair Procedures

PMS6 - Improved Outcomes and Neutral Hospital Budget Impact Associated with Flowable Gelatin for Lumbar Surgery in a Chinese Tertiary Care Hospital: A Retrospective Case-Series Study

To assess the clinical and economic impact of flowable gelatin hemostatic matrix (SURGIFLO®) for lumbar surgery (LS) in a Chinese tier III hospital, the first such real-world outcomes study in LS. Patients operated by one surgeon for lumbar disc herniation or disc stenosis from 2014-2016 in a Chinese tier III hospital were included. Historical control cohort (HC) comprised patients who underwent LS in 2014 before the introduction of SURGIFLO®. Flowable gelatin cohort (FG) comprised patients who received SURGIFLO® during LS in 2015-2016. From patient medical records and hospital cost data, propensity score and regression analyses were conducted for adjusted comparisons of surgical outcomes and hospital expenses between cohorts. 64 pairs of patients matched from FG (n=108) and HC (n=82) had well balanced patient characteristics and procedure characteristics, e.g. lumbar fusion level and procedure method (posterior lumbar interbody fusion or minimally invasive surgery transforaminal lumbar interbody fusion). In matched HC, oxidized regenerated cellulose or collagen were the most frequently utilized hemostatic products (92.7%). Matched comparisons also observed that FG was associated with significantly lower: blood transfusion rate (34.4% vs. 64.1%, p=0.005), blood transfusion volume (183 ± 312 vs. 301 ± 281 mL, p=0.045), and post-operation drainage tub placement rate (82.8% vs. 93.8%, p=0.046). Multiple regression analysis confirmed the significantly lower blood transfusion risk (odds ratio 0.115, p<0.001) and blood transfusion volume (coefficient -101.820, p=0.003) associated with FG, and showed comparable total hospital costs between cohorts (coefficient -0.001, p=0.972). Patients who received FG in LS within the Chinese tertiary care setting, compared to those who received oxidized regenerated cellulose or collagen, show significantly reduced rate and volume of blood transfusion. In addition, utilization of FG in LS did not increase hospitalization expenses. These results warrant further study to confirm the positive findings on a larger scale.

OP164 Hospital Budget Impact Of High-Cost Drugs: The Case Of Nusinersen

Introduction:Nusinersen is an orphan drug for spinal muscular atrophy (SMA) recently approved for marketing. Its high cost, striking but limited evidence of efficacy, and strong demand by media and patient organizations have generated a health policy conflict. We analyze the flaws of available evidence on nusinersen and its budget impact at a pediatric hospital, and report a collaborative strategy for drug procurement and financing.Methods:Nusinersen is the highest-cost drug assessed by our hospital-based health technology assessment (HB-HTA) program so far. At the time of our assessment, only interim-analysis data of the pivotal randomized trial submitted to Federal Drug Administration (FDA) for approval and the European Medicines Agency (EMA) report containing unpublished final results were available. These secondary sources and other published phase II results were appraised. As a referral hospital, we concentrate most of the 300 SMA patients in our country. Hospital budget impact estimation included drug and hospitalization costs for the first and following years. The HTA report was submitted to the Ministry of Health to address this financing issue.Results:The available evidence of efficacy raised serious methodological and clinical uncertainties. First-year treatment cost per patient was estimated in ARS 13,008,688 (USD 752,000, 10 percent of pharmacy annual drug budget). Hospital budget impact (70 eligible patients) was ARS 910,608,160 (USD 52,000,000; 18 percent of total annual hospital budget). Our recommendation was to contact central level authorities to resolve both drug financing and patient access by negotiating a shared-risk approach for an expanded access program, allowing further data collection for reassessment after 12 months. This, in turn, fostered mutual collaboration and consensus within the health system where several lawsuits were demanding drug coverage. Negotiation with the industry was initiated by the Ministry.Conclusions:This case is a clear example of forthcoming ultra-high-cost drugs unaffordable by hospital budgets. Their acquisition opportunity cost is a health policy matter requiring to display collaborative coping strategies with Ministries and other stakeholders including industry.

Impact économique à l’hôpital de dispositifs médicaux non remboursés en sus des GHS : exemple des prothèses de renfort biologiques

To present a method aimed to evaluate the economic impact associated with the use of medical devices (DM) not reimbursed in addition to diagnosis related groups (DRGs) tariffs using the example of biological meshes for parietal reinforcement. In this multicenter retrospective cohort study, we included all patients who received a biological mesh between January2010-April2014 (University hospitals of Saint-Étienne, France) or between January2010-March2015 (Lyon University hospitals, France). Measured costs associated with biologic meshes were compared to those of the "Étude nationale des coûts à méthodologie commune" (2012) to weigh the economic impact of biologic meshes with the French DRGs costs. We also compared these costs to the fares perceived by the hospital from the French sickness fund (GHS). Thirty-six patients received a biological mesh and were treated by a total of 38biological meshes. Of these, the implant was Protexa®, Permacol® and Strattice® in 66%, 29% and 5% of cases respectively. The hospitals incomes were 10,496±5562€ per stay. Meshes-related expenditures represented in average 28% of DRGs costs and 38% of GHS tariffs. The mean additional cost for biological meshes was 3793±2292euros compared to the mean cost on implantable medical devices in the French DRGs. Given their currently restricted use, the hospital budget impact of biological meshes remains limited although the incremental cost per patient is substantial. Analytic costs data can be useful within the scope of decision-making related to DM not refunded by the French health system.

Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis.

Background and ObjectiveNearly 10 % of all US hospital admissions are attributed to acute bacterial skin and skin structure infections (ABSSSIs). While most antibacterials used to treat these infections require multi-day and multi-dose regimens, a single-dose treatment is now available. The objective of this analysis is to estimate the annual budget impact of using single-dose oritavancin in patients with moderate to severe ABSSSIs receiving intravenous methicillin-resistant Staphylococcus aureus (MRSA)-active antibacterials from a US hospital perspective.MethodsA decision-analytic model based on current clinical practice was developed to estimate the economic impact of oritavancin. Utilization of antibacterials and rates of hospital admission were derived from the Premier Research Database. Demographic and clinical data were informed by the published literature and 2014 wholesale drug acquisition costs were used. Other costs were based on the published literature and Medicare National Limitation amounts. All costs were inflated to 2014 US dollars. Two base-case scenarios were considered: one for hospitals with ambulatory services and one for hospitals without ambulatory services.ResultsFor a US hospital with ambulatory services with 1000 ABSSSI patients receiving intravenous MRSA antibiotics annually, use of oritavancin in 26 % of patients is estimated to reduce the total annual budget by 12.9 % (US$1.23 million), or approximately US$1234.67 per patient. Total inpatient costs will be reduced by 22.3 % (US$1.40 million) and outpatient costs will increase slightly by 1.7 % (US$55,310). Pharmaceutical cost increases are offset by savings in the inpatient setting from fewer hospital admissions. Hospitals without ambulatory services are estimated to receive overall cost savings of 9.3 % (US$0.63 million).ConclusionUse of single-dose oritavancin in select ABSSSI patients with suspected or confirmed MRSA involvement is estimated to save US hospitals approximately 9.3–12.9 % per year by reducing hospital admissions and lowering drug administration burden.Electronic supplementary materialThe online version of this article (doi:10.1007/s40261-015-0365-8) contains supplementary material, which is available to authorized users.

Budget Impact of Percutaneous Endovascular Abdominal Aorta Aneurysm Repair (PEVAR) Compared to Standard Endovascular Repair in Canadian Hospitals

Budget Impact of Percutaneous Endovascular Abdominal Aorta Aneurysm Repair (PEVAR) Compared to Standard Endovascular Repair in Canadian Hospitals

PIN32 - Use of Oritavancin for the Treatment of Skin and soft Tissue Infections: A Uk Hospital Budget Impact Analysis

PIN32 - Use of Oritavancin for the Treatment of Skin and soft Tissue Infections: A Uk Hospital Budget Impact Analysis